問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

National Taiwan University Hospital

List

3348Cases

2010-03-01 - 2012-07-31

Phase III

A 24-week, multicentre, randomised, double-blind, age-stratified, placebo controlled phase III study with a 28-week extension period to evaluate the efficacy and safety of dapagliflozin 10 mg once daily in patients with type 2 diabetes, cardiovascular disease and hypertension, who exhibit inadequate glycaemic control on usual care

  • Condition/Disease

    type 2 diabetes

  • Test Drug

    dapagliflozin

Participate Sites
9Sites

Terminated9Sites

2010-08-01 - 2012-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2010-01-08 - 2011-07-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2009-01-01 - 2010-06-30

Phase III

Evaluation Dapagliflozin inhibitor and with Metformin and controls DPP-4 (Sitagliptin) and received unilateral Metformin Metformin therapy with poor glycemic control in diabetic adult still disease international efficacy and safety of 24 weeks after a second type, multi-center, Random assignment, parallel, double-blind, curative effect control group, phase III clinical trial.

  • Condition/Disease

    Patients with type 2 diabetes who still have poor blood sugar control after taking at least 1,500 mg of Metformin daily

  • Test Drug

    Dapagliflozin/placebo; Sitagliptin/placebo

Participate Sites
8Sites

Terminated8Sites

2004-07-01 - 2006-08-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2006-10-01 - 2010-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2006-12-01 - 2008-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2006-12-01 - 2009-03-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2006-03-01 - 2010-01-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2008-08-15 - 2009-02-28

Phase IV

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

1 194 195 196 197 198 335
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB